A5100664628- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Immune Cell Function and Interaction
- Cancer survivorship and care
- Viral-associated cancers and disorders
- Cutaneous lymphoproliferative disorders research
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Immunodeficiency and Autoimmune Disorders
- Retinoids in leukemia and cellular processes
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Cancer Mechanisms and Therapy
- Transplantation: Methods and Outcomes
- Renal Transplantation Outcomes and Treatments
- COVID-19 and healthcare impacts
- Cytomegalovirus and herpesvirus research
- Platelet Disorders and Treatments
Ulsan University Hospital
2019-2024
University of Ulsan
2019-2024
Ulsan College
2019-2024
Seoul National University
2024
Kangwon National University
2023
Keimyung University
2022
Kyungpook National University Hospital
2010-2020
Inje University
2019
Kyungpook National University
2012
We performed a prospective study to determine the efficacy and safety of rituximab including chemotherapy in CD20-positive acute lymphoblastic leukemia (ALL).Patients with newly diagnosed ALL, aged ≥ 15 years, were eligible for if their leukemic blast cells bone marrow expressed CD20 20% at time diagnosis. Patients received multiagent rituximab. After achieving complete remission (CR), patients five cycles consolidation concomitant Rituximab was administered monthly from day 90...
This study was performed to assess if a recently recommended genomic classification is predictive in patients with normal-karyotype (NK) acute myeloid leukemia (AML). A total of 393 were included. Analysis genetic mutations using targeted resequencing an Illumina Hiseq 2000. We identified driver across 40 genes, one or more 95.7% patients. The molecular subclassification as follows: 34.6% (n = 136) AML the NPM1 mutation, 10.7% 42) mutated chromatin RNA-splicing genes both, 1.5% 6) TP53...
Abstract In multiple myeloma (MM), a high number of focal lesions (FL) detected using positron emission tomography/computed tomography (PET/CT) was found to be associated with adverse prognosis. To design new risk stratification system that combines the Revised International Staging System (R-ISS) FL, we analyzed data 380 patients newly diagnosed MM (NDMM) who underwent 18 F-fluorodeoxyglucose ( F-FDG) PET/CT upon diagnosis. The K-adaptive partitioning algorithm adopted define subgroups...
Multiple myeloma (MM) is a hematological cancer causing from accumulated abnormal plasma cells. STAT3 overexpression in MM appears to be mediated by variety of factors, and it may associated with an adverse prognosis play role microenvironment-dependent treatment resistance. Unfortunately, remains incurable disease, as relapse very common. Therefore, there urgent need develop new options for MM. Radotinib novel anti-cancer drug, currently approved South Korea the chronic myeloid leukemia...
e14549 Background: As microRNAs play important roles in cancer development and progression by regulating the expressions of oncogenes tumor suppressor genes though interacting with 3′ untranslated region (UTR) target genes, we aimed to evaluate association between genetic variants miRNAs their binding sites prognosis patients colorectal (CRC). Methods: Three miRNA four were selected based on allelic frequencies potential impact described previous studies. DNA was extracted from fresh-frozen...
Background/Aims This study investigated the expression of nuclear factor κB (NF-κB) and chemokine receptor (CXCR4) in patients with diffuse large B-cell lymphoma (DLBCL) who received rituximab-based therapy. Methods Seventy DLBCL treated rituximab-CHOP (R-CHOP) were included, immunohistochemistry was performed to determine NF-κB (IκB kinase α, p50, p100/p52) CXCR4. To classify cases as germinal center B-cell-like (GCB) non-GCB, additional immunohistochemical CD10, bcl-6, or MUM1 used this...
Abstract Although nilotinib has improved efficacy compared to imatinib, suboptimal response and intolerable adverse events ( AE s) limit its effectiveness in many patients with chronic myeloid leukemia phase CML ‐ CP ). We investigated the 2‐year safety of their relationships plasma concentrations PNC s). In this open‐label, multi‐institutional 4 study, 110 Philadelphia chromosome‐positive were treated at a starting dose 300 mg twice daily. Molecular responses MR s monitored for up 24...
Cancer is a leading cause of death in Korea. To protect the autonomy and dignity terminally ill patients, Life-Sustaining Treatment Decision-Making Act (LST-Act) came into full effect Korea February 2018. However, it unclear whether LST-Act influences decision- making process for life-sustaining treatment (LST) cancer patients.This was retrospective study conducted with medical record review patients who died at Ulsan University Hospital between July 2015 May 2020. Patients were divided two...
Allogeneic hematopoietic stem-cell transplantation (HCT) is the only curative option for most hematologic malignancies. However, HSCT can cause early menopause and various complications in premenopausal women. Therefore, we aimed to investigate risk factors predicting its clinical implications among survivors post HCT.We retrospectively analyzed 30 adult women who had received HCT at status between 2015 2018. We excluded patients autologous stem cell transplantation, relapsed, or died of any...
Carfilzomib, lenalidomide, and dexamethasone (KRd) combination therapy improves the survival of patients with relapsed and/or refractory multiple myeloma (RRMM). Nonetheless, evidence on use KRd in Asian populations remains scarce. Accordingly, this study aimed to investigate regimen's efficacy a large group patients. This retrospective included RRMM who were treated at 21 centers between February 2018 October 2020. Overall, 364 (median age, 63 years). The overall response rate was 90%...
Abstract The effects of GM‐/G‐CSF and darbepoetin‐α on stem cell mobilization were investigated. From February 2005 to March 2007, 30 allogeneic sibling donors randomly assigned a G‐CSF group (5 μg/kg/day for 5–7 days) or triple (GM‐CSF 10 1st 2nd day, 5 days, 40 mg day). MNCs CD34 + cells not different between the two groups, although doses (×10 8 /kg recipient body weight) CD3 (3.64 ± 1.75 vs. 2.63 1.36, P = 0.089) CD8 (1.07 0.53 0.60 0.30, 0.006) lower in group. engraftments, frequency...
Purpose The aims of this study were to evaluate the diagnostic performance 18 F-florbetaben PET/CT for detecting amyloid deposits in patients with multiple myeloma (MM) and identify optimal PET analysis method. Methods Fourteen MM prospectively enrolled (6 amyloidosis, 8 control subjects). Dynamic imaging kidneys was performed 20 minutes, retention ratio obtained. At 90 minutes after injection, performed. All images assessed qualitatively quantitatively, SUVmax, SUVmean, SUVratio Variables...
Abstract Background Acute myeloid leukemia (AML) is a heterogeneous disease that frequently relapses after standard chemotherapy. Therefore, there need for the development of novel chemotherapeutic agents could treat AML effectively. Radotinib, an oral BCR-ABL tyrosine kinase inhibitor, was developed as drug treatment chronic leukemia. Previously, we reported radotinib exerts increased cytotoxic effects towards cells. However, little known about combining with Ara-C, conventional agent AML,...